BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

A new $310 million series C round for Everest is the largest venture round yet for an Asian therapeutics developer, and could set the cross-border licensing and development company up for an IPO at a...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites  In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BC Extra | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal  Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Dec 3, 2019
Financial News

Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum

Alphamab Oncology is aiming to raise about HK$1.7 billion ($221.1 million) in an IPO on the Hong Kong stock exchange next week in an offering that would value the company at HK$8.7 billion if priced...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
Items per page:
1 - 10 of 12
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

A new $310 million series C round for Everest is the largest venture round yet for an Asian therapeutics developer, and could set the cross-border licensing and development company up for an IPO at a...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BioCentury | May 15, 2020
Product Development

May 14 ASCO Quick Takes: Alphamab rises on responses for pair of bispecific mAbs; plus ImmunoGen and CytomX

Alphamab bispecifics against checkpoints, pair of HER2 sites  In an abstract released ahead of this month’s American Society of Clinical Oncology virtual meeting, Alphamab Oncology Ltd. (HKEX:9966) reported data from a Phase I trial showing...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BC Extra | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal  Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Dec 3, 2019
Financial News

Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum

Alphamab Oncology is aiming to raise about HK$1.7 billion ($221.1 million) in an IPO on the Hong Kong stock exchange next week in an offering that would value the company at HK$8.7 billion if priced...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
Items per page:
1 - 10 of 12